Reinstein Dan Z, Pradhan Kishore R, Carp Glenn I, Archer Timothy J, Day Alexander C, Sekundo Walter, Dhungana Purushottam
J Refract Surg. 2019 Jan 1;35(1):24-30. doi: 10.3928/1081597X-20181025-01.
To evaluate visual and refractive outcomes of small incision lenticule extraction (SMILE) for hyperopia.
This prospective study of vertex-centered hyperopic SMILE used the VisuMax femtosecond laser (Carl Zeiss Meditec, Jena, Germany). Inclusion criteria were maximum attempted hyperopic meridian of between +1.00 and +7.00 diopters (D) and corrected distance visual acuity (CDVA) of 20/40 or better. Lenticule parameters were 6.3- to 6.7-mm diameter, 2-mm transition zone, 30-µm minimum thickness, and 120-µm cap thickness. Standard outcomes analysis was performed for the 3-month data, including contrast sensitivity using the Functional Vision Analyzer.
For 93 eyes treated, 3-month data were available for 82 (88%). Attempted spherical equivalent refraction was +5.62 ± 1.20 D (range: +1.00 to +6.90 D) and cylinder was -0.91 ± 0.68 D (range: 0.00 to -3.50 D). For eyes targeted for emmetropia (n = 36), uncorrected distance visual acuity was 20/40 or better in 89%. Spherical equivalent refraction relative to target was -0.17 ± 0.85 D (range: -2.20 to +3.00 D), with 59% within ±0.50 D and 76% within ±1.00 D. There was one line loss of CDVA in 17% of eyes, and one eye lost three lines (1.2%) but recovered to one line lost at 9 months. There was no clinically significant change in contrast sensitivity.
Refractive and visual outcomes 3 months after SMILE for hyperopia were promising, given the high degree of hyperopia corrected and relatively reduced CDVA in this population. Undercorrection of more than 1.00 D in 5 eyes might be partly explained by latent hyperopia in these young patients. [J Refract Surg. 2019;35(1):24-30.].
评估小切口透镜切除术（SMILE）治疗远视的视觉和屈光效果。
这项以顶点为中心的远视性SMILE前瞻性研究使用了VisuMax飞秒激光（德国耶拿卡尔蔡司医疗技术公司）。纳入标准为最大尝试远视子午线在+1.00至+7.00屈光度（D）之间，矫正远视力（CDVA）为20/40或更好。透镜参数为直径6.3至6.7毫米、过渡区2毫米、最小厚度30微米和帽厚度120微米。对3个月的数据进行了标准结果分析，包括使用功能性视力分析仪进行对比敏感度分析。
93只接受治疗的眼睛中，82只（88%）有3个月的数据。尝试的等效球镜度为+5.62±1.20 D（范围：+1.00至+6.90 D），柱镜度为-0.91±0.68 D（范围：0.00至-3.50 D）。对于目标为正视眼的眼睛（n = 36），89%的未矫正远视力为20/40或更好。相对于目标的等效球镜度为-0.17±0.85 D（范围：-2.20至+3.00 D），59%在±0.50 D以内，76%在±1.00 D以内。17%的眼睛CDVA下降了一行，一只眼睛下降了三行（1.2%），但在9个月时恢复到下降一行。对比敏感度无临床显著变化。
鉴于该人群中矫正的远视度数较高且CDVA相对降低，SMILE治疗远视3个月后的屈光和视觉效果良好。5只眼睛欠矫超过1.00 D可能部分归因于这些年轻患者的潜在远视。[《屈光手术杂志》。2019；35(1):24 - 30。]
